-+ 0.00%
-+ 0.00%
-+ 0.00%

Eupraxia Pharmaceuticals Q3 Net Loss More Than Doubles to USD 15.2 Million

PUBT·11/10/2026 21:04:46
Listen to the news
Eupraxia Pharmaceuticals Q3 Net Loss More Than Doubles to USD 15.2 Million
  • Eupraxia Pharmaceuticals' third-quarter 2026 net loss more than doubled year over year to USD 15.2 million.
  • Cash and cash equivalents totaled USD 75.2 million at September 30, 2026, with short-term investments of USD 51.2 million.
  • The Phase 2b RESOLVE trial of EP-104GI reached its 120-patient enrollment target; interim results are expected in December 2026.
  • Existing cash reserves are expected to fund operations into the second half of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101601PRIMZONEFULLFEED9874793) on November 10, 2026, and is solely responsible for the information contained therein.